Actavis At 4: Where Pay-For-Delay Litigation Stands

It has been four years since the U.S. Supreme Court ruled that brand-name drugmakers' payments to generics companies in patent settlements can raise antitrust concerns, but despite calls for clarity on...

Already a subscriber? Click here to view full article